Welcome to the Rare Kidney Stone Consortium

Our Mission

The Consortium facilitates cooperative exchange of information and resources among investigators, clinicians, and patients, and researchers in order to improve care and outcomes for patients with rare stone diseases.  The consortium promotes ready availability of diagnostic testing, pooling of clinical experiences, and availability of tissue banks in order to advance the science. Our goals are to:

  • Establish and expand registries and collaborate with patient organizations for the rapid dissemination of knowledge
  • Stimulate generation of testable hypotheses regarding mechanisms of renal injury in these diseases through registry findings, tissue resources, and pilot projects
  • Develop cohorts of well-characterized patients for future clinical studies
  • Attract and train investigators to rare diseases research in nephrology

News and Upcoming Events

RFA Training and Pilot Programs

NYC DENT Patient Meeting Saturday October 14, 2017

Consortium Structure

The Rare Kidney Stone Consortium is an organization of diverse participants and independent efforts representing four major diseases of hereditary nephrolithiasis.

Consortium Administration

  • Director | Dawn S. Milliner, M.D. | bio
  • Associate Director | John C. Lieske, M.D. | bio
  • Primary Hyperoxaluria Program Director | Dawn S. Milliner, M.D. | bio
  • Cystinuria Program Director | David Goldfarb, M.D. | bio
  • Dent Disease Program Director | John Lieske, M.D. | bio
  • APRT Deficiency Program Director | Vidar Edvardsson, M.D. | bio

Advocacy Organizations

Additional Resources

Study Sites and Participating Organizations